Athena Athena

X
[{"orgOrder":0,"company":"Mutabilis","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","amount":"$11.9 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Holdings REPAIR Impact Fund Invests USD 12 Million in Mutabilis and IBT Vaccines and Provides Strategic Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"Mutabilis","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$5.8 million","upfrontCash":"Undisclosed","newsHeadline":"Carb-X Is Funding Mutabilis to Develop New Class of Antibacterials for Infections Caused by Carbapenem-Resistant Enterobacterales Bacteria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Mutabilis

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Mutabilis’ new intravenous drug, EBL-1463, is a novel class of non-beta-lactam inhibitor of penicillin binding proteins (PBPs) called dabocins. Mutabilis’ new drug aims to treat deadly ‘nightmare bacteria’ infections safely and effectively.

            Lead Product(s): EBL-1463

            Therapeutic Area: Infections and Infectious Diseases Product Name: EBL-1463

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: CARB-X

            Deal Size: $5.8 million Upfront Cash: Undisclosed

            Deal Type: Funding February 03, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This investment will allow the Mutabilis to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.

            Lead Product(s): 2G-Dabocins

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Organovo Holdings

            Deal Size: $11.9 million Upfront Cash: Undisclosed

            Deal Type: Investment January 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY